All In Biotech

Drug Trial Radar · NCT01034306

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors

Last checked: Nov 20, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

79

Actual

Start

Oct 2010

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Dec 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.

Conditions

  • Rheumatoid Arthritis

Interventions

  • CF101Drug

    orally q12h

  • Placebo controlDrug

    orally q12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)Time frame: 12 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Multiprofile Hospital for Active Treatment

    Sofia, Bulgaria

  • Diagnostic Consultative Center Sofia

    Sofia, Bulgaria

  • Military Medical Academy

    Sofia, Bulgaria

  • UMHAT "Sveti Ivan Rilski", Rheumatoloty Clinic

    Sofia, Bulgaria

  • Barzilai Medical Center

    Ashkelon, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.